Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $175.53, for a total transaction of $2,632,950.00. Following the completion of the transaction, the director now directly owns 534,176 shares of the company’s stock, valued at $93,763,913.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded down 0.41% during midday trading on Thursday, hitting $173.76. 1,215,747 shares of the stock traded hands. The stock has a market cap of $25.37 billion, a price-to-earnings ratio of 35.17 and a beta of 0.79. The company’s 50 day moving average price is $178.76 and its 200-day moving average price is $157.71. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $189.48.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, hitting the consensus estimate of $0.64. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The business had revenue of $598 million for the quarter, compared to analyst estimates of $590.51 million. During the same quarter in the previous year, the firm earned $0.71 EPS. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts expect that Illumina, Inc. will post $3.63 EPS for the current year.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

TRADEMARK VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/05/25/insider-selling-illumina-inc-ilmn-director-sells-15000-shares-of-stock.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Baillie Gifford & Co. raised its position in Illumina by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 18,766,712 shares of the life sciences company’s stock valued at $2,402,890,000 after buying an additional 178,559 shares in the last quarter. Vanguard Group Inc. raised its position in Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock valued at $1,646,479,000 after buying an additional 285,379 shares in the last quarter. Edgewood Management LLC raised its position in Illumina by 33.6% in the fourth quarter. Edgewood Management LLC now owns 6,639,776 shares of the life sciences company’s stock valued at $850,157,000 after buying an additional 1,671,293 shares in the last quarter. Jennison Associates LLC raised its position in Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Illumina by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 4,632,576 shares of the life sciences company’s stock valued at $841,554,000 after buying an additional 140,411 shares in the last quarter. Institutional investors and hedge funds own 92.79% of the company’s stock.

Several research analysts have recently weighed in on the stock. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $190.90 price objective for the company in a report on Tuesday, April 4th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price objective for the company in a report on Tuesday, April 4th. Leerink Swann reissued a “buy” rating on shares of Illumina in a report on Wednesday, April 5th. Morgan Stanley restated an “underweight” rating and set a $115.00 target price (up from $108.00) on shares of Illumina in a research report on Monday, May 15th. Finally, Canaccord Genuity restated a “hold” rating and set a $150.00 target price on shares of Illumina in a research report on Tuesday, February 21st. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $165.02.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

12 Month Chart for NASDAQ:ILMN

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.